Copaxone

MS Patients More Compliant with Medications When Managed by Specialty Pharmacy, According to HealthCore Study Presented at ISPOR

...naged. The median age was 46 years and the majority was female. More than one-third of the patients used Avonex as index medication, while others used copaxone (31 percent), Rebif (17 percent), Betaseron (14 percent) and Tysabri (less than 1 percent). About HealthCore HealthCore, based in Wilmington,...

Sanofi-aventis Announces Good First-quarter 2009 Performance

...ainly impacted (-3.3%) by the end of commercialization by sanofi-aventis of copaxone (R) in North America effective April 1, 2008; this has no impact on net ...nks to a good performance in Japan. The end of commercialization of copaxone (R) by sanofi-aventis in North America effective April 1, 2008 led to a 63....

Best treatment for MS may depend on disease subtype

...lready know that some people respond better to the drugs beta interferon or copaxone than others. Now we've shown proof that you can cause MS-like syndrome in m...have attacks again. In the last 15 years, several beta interferon drugs and copaxone have been effective in many patients at limiting the number of attacks. The...

New data show patients using avonex reported less sick leave and short-term disability costs

...sick leave costs and short-term disability costs than patients treated with copaxone (glatiramer acetate). "It is clear that a key priority in the treatment ... the four DMTs: AVONEX patients reported 42 percent less sick leave than copaxone (2.98 days/year vs. 7.18 days/year; P≤0.01) About the Study ...

Significant Barriers Prevent People with MS from Fully Committing to Treatment Regimen, New Survey Reveals

...clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 Aug 4; 370(9585): 389-97 (3) copaxone Prescribing Information (4) Baum K, O'Leary C, Coret-Ferrer F, Klimova E, Prochazkova L, Bugge J; for BRIGHT Study Group. Comparison of injectio...

Many American senior citizens fall into the “Doughnut Hole”!

...rescriptions in May. Wife Diane's prescriptions include a daily shot of copaxone worth about $1,300 a month for multiple sclerosis. "Even though I knew it ... percent of her drug costs until the end of December. One month's supply of copaxone now costs them just $68. Part D is well worth its cost for the Murphys....

Drug Combo Improves Performance Of Multiple Sclerosis Drug

...at selectively inhibits the destruction of myelin. copaxone treatment however is effective only in about 30- 3... Although Lipitor produces the same effect as copaxone (through a different mechanism), the clinical and ...ed when the drug combination is used. Low doses of copaxone or Lipitor, on the other hand did not have any ben...

Copaxone in Medical Technology

Data on Higher Dose of Copaxone and Data Showing Copaxone is Most Cost Effective

Data Published in Neurology Showed That Higher Dose of Copaxone Increased Efficacy in Relapsing-remitting Multiple Sclerosis (RRMS) Doubled Dose of COPAXONE Maintained Proven Safety Profile and Further Reduced Relapses and Lesions JERUSALEM, Israel, April 17, 2007 – A 9-month, rando...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis Combination Treatment With Antibiotic Further Reduced Brain Lesions and Was Well Tolerated KANSAS CITY, Mo, May 4, 2007 - New data from a ran...

Treatment with Copaxone Plus Minocycline Showed Substantial Reduction of Disease Activity in Patients with Active Relapsing-Remitting Multiple Sclerosis

KANSAS CITY, Mo.--(BUSINESS WIRE)--May 4, 2007 - New data from a randomized, double-blind study showed that a combination of COPAXONE(R) (glatiramer acetate injection) along with the oral antibiotic minocycline reduced T1 Gadolinium (Gd)-enhancing lesions of the brain by 63 percent (p=0.08) in pati...

Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line

... drug-treatment rate in newly diagnosed patients. "Surveyed neurologists' responses suggest that Biogen Idec's Avonex is more at-risk than Teva's copaxone of losing share upon the launch of either oral cladribine or fingolimod, as more physicians cite Avonex as having potential for being replaced by eith...

Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis

...o be more efficacious and more convenient (weekly versus daily dosing) than copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modul...and, in preclinical studies, has shown to be more potent and effective than copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown e...

Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008

...301 has been optimized using Peptimmune's novel platform peptide chemistry and, in preclinical studies, has shown to be more potent and effective than copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown efficacy in preclinical models of autoimmune diseases where immune modulatio...

Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings

...along with the significant improvements on bioavailability and pharmacodynamic effects with PI-2301, provide further evidence that PI-2301 may replace copaxone as first-line therapy in relapsing remitting multiple sclerosis," stated Thomas P. Mathers, President and CEO of Peptimmune. "We have designed PI-2301...

More>>

Copaxone in Medical Dictionary

Sclerosis

...cluding diet, exercise, rehabilitation, and mental health recommendations to lead a more fullfilling life with this ... If you are considering copaxone as a treatment for multiple sclerosis , you need to know the facts about Copaxone's side effects, efficacy, cost, contraindications, ... Vision...

Copaxone in Biological News

Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone

A group of Israeli scientists from the Technion Israel Institute of Technology, the Weizmann Institute of Science and Teva Pharmaceutical Industries have recently identified genes responsible for the positive response of many multiple sclerosis patients to the drug Copaxone®. These findings m...

'Buckyballs' to treat multiple sclerosis

...o have been diagnosed with MS, where approximately 200 new cases are diagnosed each week. Current state-of-the-art therapies like the Israeli-invented copaxone clearly help, but may not be enough, says Dr. Gozin, whose wide-ranging research has included work on classified projects for the U.S. Department of D...

Copaxone in Biological Technology

Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis

Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over an Interferon-Beta Therapy, According to a New Report from Decision Resources WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory f...

Sanofi-aventis Announces Second Quarter 2009 Results

...op (of 0.6%) in second-quarter net sales to euro 191 million. First-half net sales held steady at euro 438 million. First-quarter net sales of copaxone ((R)) were up 16.5% at euro 118 million. The end of commercialization of this product by sanofi-aventis in North America - effective April 1, 2008 -...

Peptimmune Presentations at Upcoming Events

...o be more efficacious and more convenient (weekly versus daily dosing) than copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modul...and, in preclinical studies, has shown to be more potent and effective than copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown e...

Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis

...o be more efficacious and more convenient (weekly versus daily dosing) than copaxone for the treatment of multiple sclerosis. PI-2301 works through immune modul...and, in preclinical studies, has shown to be more potent and effective than copaxone in treating disease models for multiple sclerosis. PI-2301 has also shown e...